Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2023-08-16 | 2023-07-21 |
| Drug Identification Number | 02441004 | 02441004 |
| Brand name | FETZIMA | FETZIMA |
| Common or Proper name | Fetzima ER 120 mg capsules | Fetzima ER 120 mg capsules |
| Company Name | ABBVIE CORPORATION | ABBVIE CORPORATION |
| Ingredients | LEVOMILNACIPRAN | LEVOMILNACIPRAN |
| Strength(s) | 120MG | 120MG |
| Dosage form(s) | CAPSULE (EXTENDED RELEASE) | CAPSULE (EXTENDED RELEASE) |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | 30 capsules bottle | 30 capsules bottle |
| ATC code | N06AX | N06AX |
| ATC description | ||
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2023-07-24 | 2023-07-24 |
| Actual start date | ||
| Estimated end date | 2023-08-15 | 2023-08-11 |
| Actual end date | 2023-08-15 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | 20, 40 & 80 mg strengths continue to remain available | 20, 40 & 80 mg strengths continue to remain available |
| Health Canada comments |